Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
MarketAxess Holdings (MKTX), once a high-flying fintech darling, has seen its share price erode by nearly 70% over five years. As the bond trading platform grapples with shifting market dynamics and increased competition, investors are left debating whether the current valuation presents a rare buying opportunity or signals deeper structural challenges.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Digital asset funds have recorded a second consecutive week of massive outflows, totaling $1.7 billion, as hawkish Fed signals and geopolitical tensions trigger a defensive shift. While Bitcoin and Ethereum led the retreat, tokenized precious metals emerged as a rare destination for new capital.
Shares of specialty insurer Kinsale Capital have tumbled over 11% in six months, starkly underperforming the surging S&P 500. As investors digest its latest earnings, the debate intensifies: Is this a rare chance to buy a high-growth company at a discount, or a signal of deeper challenges ahead?
In a rare break from Wall Street's typically optimistic consensus, a handful of prominent stocks are receiving bearish price targets that signal deep-seated concerns. We examine the challenges facing Deckers, MSC Industrial, and Guardant Health, and why investors might want to look elsewhere.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
Investment firm Tanager Wealth Management has fully divested its position in Centessa Pharmaceuticals, capitalizing on the biotech's near-60% annual surge. The move highlights strategic portfolio rebalancing as the stock's rally potentially amplified its risk profile within a diversified fund.
In a rare firsthand account, Dr. Mohamed Ibrahim details his three-day escape from el-Fasher as paramilitary forces overran the city. His testimony paints a harrowing picture of urban warfare, civilian slaughter, and the systematic collapse of Sudan's last army bastion in Darfur.
Fair Isaac Corporation (FICO), the analytics software giant behind the ubiquitous credit score, has seen its shares retreat from multi-year highs. This pullback has investors debating whether the dip presents a rare entry point or signals that the stock's premium valuation is finally facing a reality check.
Former CNN anchor Don Lemon faces federal charges under the Freedom of Access to Clinic Entrances (FACE) Act after a protest at a Minnesota church, marking a rare application of the law beyond abortion clinic demonstrations and raising First Amendment questions.
In a market often swayed by hype, starkly bearish analyst targets are a rare signal. We examine three such cases: two consumer giants where the pessimism may be overdone, and one high-flyer where the concerns might be justified.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
Charter Communications reversed a year-long decline in its pay-TV business, adding 44,000 video subscribers in Q4. The unexpected turnaround, driven by simplified pricing and bundled streaming, offers a rare bright spot for a sector grappling with soaring costs and cord-cutting.
Shares of Corcept Therapeutics plunged 16% after a corrected FDA letter disclosed the agency had repeatedly cautioned the company against filing its application for a Cushing's syndrome drug, which was later rejected over efficacy and safety concerns.
